RxDoctor Payments Data

Mary Wiles, DO

Internal Medicine · Blairsville, GANPI 1598056897

Payments from drug & device makers

$9,661in general payments, 2019–2025

Across 416 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Novo Nordisk$887
  • Corcept Therapeutics$814
  • Bayer$621
  • Lilly USA, LLC$480
  • Pfizer$477
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$9,641100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,661 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$507,212
Medicare patients
453
Services billed
8,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$111,352
EliquisApixaban73$98,812
TymlosAbaloparatide23$65,993
Repatha SureclickEvolocumab49$56,861
JardianceEmpagliflozin41$43,595
TrulicityDulaglutide38$40,945
MounjaroTirzepatide28$38,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$38,593
Repatha PushtronexEvolocumab35$36,209
ArexvyRsvpref3 Antigen/As01e/Pf79$23,990
EntrestoSacubitril/Valsartan12$23,228
XareltoRivaroxaban17$23,025
KerendiaFinerenone14$21,847
FarxigaDapagliflozin Propanediol14$19,219
VeltassaPatiromer Calcium Sorbitex12$11,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$887$111,35270 claims
PfizerEliquis$477$98,81273 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta, Incruse Ellipta$303$83,733186 claims
Lilly USA, LLCTrulicity, Mounjaro$480$79,89066 claims
Radius Health, Inc.Tymlos$470$65,99323 claims
Boehringer IngelheimJardiance$266$43,59541 claims
NovartisEntresto$266$23,22812 claims
Johnson & JohnsonXarelto$27$23,02517 claims
BayerKerendia$621$21,84714 claims
AstraZenecaFarxiga$274$19,21914 claims
Sumitomo Pharma America, Inc.Gemtesa$418$10,23312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Blairsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →